Health insurance reimbursement in Europe is organised country by country, not at the EU level. Each member state runs its own statutory health insurance system, coverage decision body, and HTA process. A CE mark under Regulation (EU) 2017/745 allows a device to be placed on the European market. It does not trigger payment anywhere. Reimbursement is a separate, parallel track — measured in years, not months — and it is the gating factor for real MedTech revenue in Europe. Founders who plan for CE and assume reimbursement will follow are the same founders who run out of runway six months after certification.

By Felix Lenhard and Tibor Zechmeister. Last updated 10 April 2026.

TL;DR

  • European health insurance reimbursement is a national competence. There is no EU-level reimbursement decision. Every country decides independently whether, how much, and under what conditions it will pay for a medical device.
  • The dominant model across Europe is statutory health insurance — public or quasi-public systems that cover the majority of the population. Private insurance exists alongside it but is a secondary channel in almost every country that matters commercially.
  • Reimbursement requires a separate evidence package from MDR certification. The MDR asks whether the device is safe and performs as intended. Payers ask whether it delivers enough clinical and economic value to justify public spending.
  • Timelines from CE marking to meaningful national reimbursement are typically multi-year. Planning for this gap is the difference between a company that reaches revenue and a company that does not.
  • Health Technology Assessment bodies sit between the device and the payer in most major markets. Their verdict is often the practical gate to coverage.

The Graz SaaS company that had everything and sold nothing

A software-as-a-service medical device company in Graz did the regulatory work the way it is supposed to be done. MDR certification — complete. Quality management system — certified. Technical documentation — passed. Notified Body — satisfied. Clinical evidence stood up. Product actually worked. By every measure used to judge MedTech regulatory execution, this company was a success story. The business model collapsed anyway.

They had assumed two things and both were wrong. First, that statutory health insurance coverage would follow the CE mark. Second, that until reimbursement caught up, patients would pay out of pocket for a certified device their doctor had recommended. Tibor's sharpest line on the second assumption: patients will spend two hundred euros on dinner without blinking, then refuse to spend fifty euros on a medical device. Not because they cannot afford it — because they expect the healthcare system to pay for medical devices. That expectation is not rational, but it is the market.

The Graz company learned this after certification was complete. After the money had been spent. After the product was on the shelf. The people who would have benefited could not get it reimbursed, and the people who could have paid did not believe they should have to. That is the gap between CE marking and European reimbursement, compressed into one company. This post exists to make sure you do not repeat it.

The basics of European reimbursement

There is no single European reimbursement system. Health policy — specifically who pays for what — is a national competence under the EU treaties. The European Commission does not decide whether a device is reimbursed in Germany, France, or Sweden. Each country decides that for itself, through its own institutions, on its own timelines, and with its own evidence thresholds.

The most common mental model of Europe is "one market, 450 million people, one regulatory process." The first half is true for regulation — Regulation (EU) 2017/745 creates a single CE-marked path to market access across the EU and the EEA. The second half is not true for payment. A CE mark gives the device permission to be placed on the market. It does not answer the only question a national health system actually cares about: does this device justify spending public money relative to what the system already pays for?

European MedTech market access is two parallel tracks on different clocks. Track one is regulatory: centralised, defined, finite. Track two is reimbursement: country by country, open-ended, much longer than most founders expect. A company that treats the regulatory track as the whole journey arrives holding a certificate and no customers.

Statutory vs private health insurance

The dominant European payer model is statutory health insurance — public or quasi-public systems funded through mandatory contributions, taxes, or a mix, that cover the large majority of the population. Architectures vary: some countries operate a single national health service that both funds and delivers care; others run statutory sickness funds under strict national coverage rules; others use a regulated multi-payer structure. The common feature is that statutory coverage decisions are made centrally under national rules, not by individual funds competing for market share.

Private health insurance exists in every European country, but its commercial role varies. In most markets it is a supplementary channel — it covers copayments, upgrades, or services outside the statutory basket. In almost no European country is private insurance the primary path to scale for a device aimed at the general population. Founders who plan a European launch around private insurance because "it is faster" are optimising for the wrong market.

European MedTech revenue lives or dies on statutory reimbursement. Private coverage can bridge early revenue, validate willingness to pay, and test commercial hypotheses. It does not carry a business at scale. The long-term plan has to route through statutory coverage sooner or later, and the sooner the plan acknowledges that, the better.

The country-by-country reality

Because reimbursement is national, European market access has to be sequenced country by country. Each target country has its own coverage decision body, HTA process, evidence thresholds, pricing negotiation mechanics, and language requirements. The same device, the same clinical dossier, and the same health economic model will land differently in Germany, France, the Netherlands, Italy, and Spain — not because any of those countries are hostile, but because each one has built its own machinery for deciding what the public system pays for.

This is why the pan-European launch fantasy — CE mark followed by twenty countries in twenty-four months — is fiction in almost every case. Documentation overlap between countries is real, but every country requires its own submission, its own dossier, and often its own local evidence. The realistic launch plan picks two or three countries to prioritise, sequences them in an order that matches the company's positioning, and treats the remaining markets as later waves.

Which countries come first depends on the device. For most inpatient hospital devices, Germany is the anchor because it is the largest single market and the structural machinery is well-defined (post 749). For digital health, Germany is also the anchor because of the DiGA fast track (post 750). For devices with a strong health economic story and surgical positioning, France is often second (post 751). The Netherlands (752), Italy (753), and Spain (754) each have their own logic. Country sequencing has to be a deliberate plan, not a default assumption that "Europe happens automatically."

The multi-year timelines

The honest timeline from CE marking to meaningful reimbursement in a new European country — for a device that does not inherit an existing reimbursed procedure — is measured in years. Not months. This is the structural consequence of systems that require clinical benefit evidence, health economic evidence, and often real-world data before they commit public money to a new intervention.

The timeline breaks into three phases. First, bridge revenue — any mechanism by which a device can generate money before permanent reimbursement exists: temporary additional payments for new hospital methods, early access schemes, private-pay pilots, paid clinical studies. Bridge revenue rarely scales, but it buys time and generates the evidence the next phase needs. Second, the coverage decision itself — the moment a payer commits, under defined conditions, to pay for the device as part of its benefit catalogue. Third, steady-state reimbursement at a rate that reflects the real cost of the device and the value it creates. Phase two to phase three often takes additional years as payment catalogues recalibrate based on actual use data.

A financial model that assumes meaningful European revenue within twelve months of CE marking has not accounted for reimbursement. A realistic model accepts the gap, finds a bridge, and funds the runway to cross it. Companies that ignore this arithmetic run out of money in the worst window: after the regulatory money is spent, before the reimbursement money arrives.

Evidence of economic value

Reimbursement evidence is not the same as regulatory evidence. The MDR asks whether the device is safe and performs as intended. Payers ask a different question: does the device produce enough clinical and economic value to justify paying for it relative to what the system already pays for? The questions overlap in the middle — both care about clinical outcomes — but they demand different dossiers.

A reimbursement evidence package typically needs, at general framing: clinical data that compares the device to a relevant standard of care rather than to placebo or to the device's own specifications; outcome data that maps to endpoints payers care about — mortality, morbidity, quality of life, resource use — rather than technical performance metrics; and a health economic model that translates clinical effect into budget impact. Payers read these packages with one question in mind: can I afford this, and is it worth it?

Article 32 of the MDR requires manufacturers of implantable and Class III devices (with defined exceptions) to draw up a Summary of Safety and Clinical Performance. (Regulation (EU) 2017/745, Article 32.) The SSCP is a regulatory document, not a reimbursement document, but it sits adjacent to the reimbursement conversation because it is the public summary of the clinical evidence underlying the CE mark. Payers increasingly read SSCPs as part of their own assessment. Writing one that engages both audiences is a compounding advantage.

The HTA layer

In most major European reimbursement decisions, a Health Technology Assessment body sits between the device and the payer. Names and mandates differ by country, but the function is structurally similar: they take the evidence dossier, assess clinical benefit against a defined comparator, run or review a health economic model, and issue an opinion the payer uses to decide coverage and price.

The HTA body is often the practical gate. A positive assessment does not guarantee coverage; a negative assessment almost always blocks it. HTA evidence standards are higher than MDR standards because they answer a harder question. A device that earned its CE mark on equivalence data and a small clinical study may be unable to clear an HTA review that demands comparative effectiveness data against the incumbent standard of care.

HTA readiness has to be baked into the clinical evidence plan from the beginning, not added after certification. Designing a pivotal study to satisfy both MDR and likely HTA requirements costs only marginally more than designing it for the MDR alone. Running a second study after certification costs many times more, takes many more years, and is often not feasible because the device is already on the market and randomisation is no longer ethical. The single most important act of reimbursement planning is writing the clinical development plan to answer payer questions from day one.

Common founder mistakes

  • Assuming a CE mark under Regulation (EU) 2017/745 translates into statutory health insurance coverage. These are parallel systems with different decision makers and different evidence requirements.
  • Planning a European rollout as "twenty countries in two years" on the strength of a single CE certificate. Every country runs its own reimbursement track, and the track is long.
  • Designing the clinical evaluation plan only for MDR and discovering after certification that HTA bodies want a different comparator, endpoint, or patient population.
  • Assuming European patients will pay out of pocket for a certified device recommended by their doctor. They will not, no matter how reasonable the price looks next to a dinner bill.
  • Treating private health insurance as the primary commercial channel because it is faster. It is faster, and also smaller, and will not carry a business at scale.
  • Building the financial model on "CE plus twelve months to revenue" without naming the bridge revenue source that covers the real gap.
  • Ignoring HTA bodies until after the CE mark is in hand. By then the clinical evidence is frozen and the cheapest window to influence it is closed.

The Subtract to Ship angle

Subtract to Ship applied to reimbursement means refusing to build evidence that does not serve a specific, named gate. Every clinical endpoint, every health economic input, every real-world data point must trace back to a decision a payer or HTA body is going to make. If it does not, it is waste, and waste under constraint kills companies (post 065).

It also means refusing to launch every European country at once. Pick the two or three markets that matter most. Sequence them. Build the evidence package that works in those markets first. Let the others wait. Every country added to the simultaneous launch plan halves the attention available for the others.

The hardest move is subtracting the assumption that CE marking and reimbursement are a single process. They are two processes that share overlapping clinical data. Planning them as one is the mistake that broke the Graz SaaS company. Planning them as two, from the first week of the clinical development plan, is the discipline that gets a device from certification to revenue without a death-spiral gap.

Reality Check — Where do you stand?

  1. Do you know which countries you plan to enter first for reimbursement, and why those and not others?
  2. Have you accepted that CE marking and reimbursement are two parallel tracks, and is your financial model built around that reality?
  3. Is your clinical development plan designed to serve both MDR certification and the HTA evidence bar in your priority markets?
  4. Have you named a bridge revenue source that covers the runway between CE marking and first meaningful national reimbursement?
  5. Do you understand the statutory health insurance system in your lead market at the level of which body makes the coverage decision and what evidence it demands?
  6. Is your health economic model built around endpoints that payers actually care about — mortality, morbidity, quality of life, resource use — rather than around the technical performance metrics the engineering team finds interesting?
  7. Have you resisted the temptation to add "twenty countries in two years" to the investor deck, or is that line still in the fundraising story?

Frequently Asked Questions

Is there a single European reimbursement system for medical devices? No. Reimbursement is a national competence. Each EU member state decides independently, using its own coverage decision body, HTA process, and evidence standards. The CE mark is European; reimbursement is country by country.

Does CE marking guarantee reimbursement anywhere in Europe? No. A CE mark under Regulation (EU) 2017/745 confirms that a device meets EU safety and performance requirements. It does not trigger coverage in any national health system. Reimbursement is a parallel process requiring additional clinical and health economic evidence beyond the MDR.

How long does reimbursement take in a new European country after CE marking? For a genuinely new technology that does not inherit an existing reimbursed procedure, the realistic timeline is years rather than months. Temporary bridge mechanisms can generate earlier limited revenue, but permanent inclusion in a national coverage catalogue typically requires multi-year evidence cycles.

Is private health insurance a viable alternative to statutory coverage in Europe? For most MedTech startups aimed at general patient populations, no. Private insurance plays a supplementary role in almost every European country. It can provide bridge revenue or test willingness to pay, but rarely carries a business at scale.

What is a Health Technology Assessment and why does it matter? HTA is the process by which national bodies evaluate the clinical and economic value of a new technology to decide whether a payer should cover it. HTA evidence standards are higher than MDR standards because they answer a harder question — not "is it safe?" but "is it worth paying for?" In most major European markets, the HTA verdict is the practical gate to reimbursement.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, Article 32 (Summary of safety and clinical performance). Official Journal L 117, 5.5.2017.
  2. Treaty on the Functioning of the European Union, Article 168 — the legal basis under which the organisation and delivery of health services, including reimbursement decisions, remain a competence of the member states.
  3. National statutory health insurance legislation in the major European markets — each country's framework is maintained by its own ministry of health and social security institutions. Always consult the current national legal text when planning a specific country entry.
  4. National Health Technology Assessment bodies across Europe — their methodological guides and evidence frameworks are the authoritative reference for reimbursement evidence planning in each country.

Current-status verification note: the reimbursement frameworks referenced in this post evolve continuously at the national level. Any operational plan based on this primer must verify the current state of the target country's statutory system, HTA process, and coverage decision mechanisms directly against the national authorities before commitments are made.

This post is part of the Funding, Business Models & Reimbursement series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. European reimbursement is the gate that decides whether a certified device becomes a real business, and the discipline of planning for it from day one is the single most underrated act of MedTech survival.